Syndax's Newly Arrived CEO Briggs Morrison Announces Clinical Collaboration With Genentech
This article was originally published in Scrip
Syndax Pharmaceuticals Inc. - which recently lured respected scientist Briggs Morrison away from AstraZeneca to be its CEO - has entered a clinical collaboration with Genentech Inc. to evaluate the safety, tolerability and preliminary efficacy of its lead asset, entinostat, an oral small molecule targeting immune regulatory cells (myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs)), in combination with the Roche Holding AG biologics division's PD-L1 inhibitor atezolizumab in patients with triple-negative breast cancer.
You may also be interested in...
Cancer-focused biotech obtains preclinical program aimed at leukemia subset involving chromosomal rearrangements. Merck acquires an interest in KalVista and rights to its diabetic macular edema candidate, while Arcturus partners with Janssen in hepatitis B.
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.